Skip to content

Study · Non-randomized trial · n = 20 · 1994

3 results

Improvement in major depression after low subcutaneous doses of MIF-1.

Ehrensing RH, Kastin AJ, Wurzlow GF, Michell GF, Mebane AH

Journal of affective disorders1 Aug 1994Cited by 29 (Europe PMC)

PMID7989637 (opens in a new tab)DOI10.1016/0165-0327(94)90098-1 (opens in a new tab)PepBankPUB-07989637
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with major depression, MIF‑1 improved all reported depression rating scales more than placebo after the first week.

    In plain wordsIn patients with major depression, MIF‑1 improved depression ratings more than placebo after the first week.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDepression rating scales after first week
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 mg daily · subcutaneous · 5 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    At the end of the first week, the group receiving MIF-1 was significantly improved on all rating scales as compared with the group receiving placebo.
    2 context sentences
    Summary · context
    In this double-blind pilot study, 20 significantly depressed patients who all met the DSM-III R criteria for major depression were given a single subcutaneous injection of either 10 mg MIF-1 (Pro-Leu-Gly-NH2) or placebo on each of 5 consecutive days.
    Summary · context
    Treatments were reversed for a second week of 5 consecutive daily injections.
  2. 02HumanNon-randomized trialEfficacy outcome

    In major depression, marked improvement occurred in 8 of 9 MIF‑1 recipients versus 2 of 11 saline recipients.

    In plain wordsIn patients with major depression, marked improvement was more frequent with MIF‑1 than saline.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseMarked depression improvement
    Study

    n = 20

    Comparator
    Saline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 mg daily · subcutaneous · 5 consecutive daysAs given in this study (human).

    Measurements

    Marked improvement
    8 patients
    MIF-1 arm of 9
    Marked improvement
    2 patients
    saline arm of 11

    Source sentences

    Summary
    Eight out of 9 patients receiving MIF-1 showed marked improvement (score < or = 7 on the Hamilton Scale) as compared with only 2 of 11 patients receiving saline (P < 0.01).
    2 context sentences
    Summary · context
    In this double-blind pilot study, 20 significantly depressed patients who all met the DSM-III R criteria for major depression were given a single subcutaneous injection of either 10 mg MIF-1 (Pro-Leu-Gly-NH2) or placebo on each of 5 consecutive days.
    Summary · context
    Treatments were reversed for a second week of 5 consecutive daily injections.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with major depression who initially received placebo, MIF‑1 during the second week produced substantial improvement.

    In plain wordsIn patients with major depression, ratings improved after treatment changed from placebo to MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDepression after crossover to MIF-1
    Study

    n = 11

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 mg daily · subcutaneous · 5 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    Administration of MIF-1 during the second week to the patients who had received placebo during the first week resulted in substantial improvement so that by the end of the second week the two groups were indistinguishable.
    2 context sentences
    Summary · context
    In this double-blind pilot study, 20 significantly depressed patients who all met the DSM-III R criteria for major depression were given a single subcutaneous injection of either 10 mg MIF-1 (Pro-Leu-Gly-NH2) or placebo on each of 5 consecutive days.
    Summary · context
    Treatments were reversed for a second week of 5 consecutive daily injections.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.